Alnylam Pharmaceuticals (ALNY) Long-Term Debt Issuances (2021 - 2025)

Alnylam Pharmaceuticals (ALNY) has 3 years of Long-Term Debt Issuances data on file, last reported at -$680000.0 in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to -$680000.0; the trailing twelve-month figure through Dec 2025 stood at -$1.5 million (down 100.14% YoY), and the FY2025 full-year result was $645.7 million, changed N/A from the prior year.
• Long-Term Debt Issuances for Q4 2025 stood at -$680000.0, up from -$777000.0 in the prior quarter.
• Across five years, Long-Term Debt Issuances topped out at $1.0 billion in Q3 2022 and bottomed at -$250.0 million in Q3 2021.
• The 3-year median for Long-Term Debt Issuances is -$728500.0 (2022), against an average of $191.4 million.
• Peak annual rise in Long-Term Debt Issuances reached 506.76% in 2022, while the deepest fall reached 506.76% in 2022.
• A 3-year view of Long-Term Debt Issuances shows it stood at -$250.0 million in 2021, then soared by 99.69% to -$777000.0 in 2022, then grew by 12.48% to -$680000.0 in 2025.
• The last three Long-Term Debt Issuances figures came in at -$680000.0 (Q4 2025), -$777000.0 (Q4 2022), and $1.0 billion (Q3 2022), per Business Quant data.

Peer Comparison